The beat-and-raise quarter supports the fundamental turnaround narrative driven by non-COVID product strength and cost discipline. The $4.3B impairment is non-cash and should not distract from operational momentum. For Q3, watch for the ~$0.10 Innovent EPS headwind and the trajectory of COVID product revenues. The CFO transition adds near-term overhang but appears orderly.
PFE drugs
PFE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 4 $25.41entry
- T+1 · 3mo ago +1.57%α +1.77% · $25.81
- T+5 · 3mo ago +4.76%α +4.86% · $26.62
- T+20 · 3mo ago +12.36%α +13.60% · $28.55
- T+60 · 20d ago +17.28%α +17.49% · $29.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pfizer reported Q2 2026 adjusted EPS of $0.77 (12.9% beat vs $0.68 consensus) and revenue of $15.0B (4.5% beat vs $14.4B consensus), raised full-year 2026 revenue guidance by $500M midpoint to $60.5-$62.5B, and reaffirmed adjusted EPS guidance of $2.80-$3.00 despite absorbing a ~$0.10 impact from the Innovent biologics transaction. Strength in non-COVID products (Eliquis +19%, Padcev +23%, Lorbrena +37%) drove 18% operational growth in launched/acquired products, offsetting COVID revenue declines, while GAAP reported a net loss of $0.04 per share due to $4.3B in non-cash intangible asset impairments.
Key Financial Metrics
Key Facts
- Adjusted diluted EPS of $0.77 beat consensus of $0.68 by 13.2%
- Revenue of $15.034B rose 3% YoY (1% operational); ex-COVID, revenue grew 5% operationally
- Full-year 2026 revenue guidance raised $500M at midpoint to $60.5-$62.5B; adjusted EPS guidance reaffirmed at $2.80-$3.00
- GAAP reported a loss of $(0.04)/share due to $4.3B in non-cash intangible asset impairments (sigvotatug vedotin $3.8B, Oxbryta $525M)
- Launched & Acquired Products grew 18% operationally; Eliquis +19%, Padcev +23%, Lorbrena +37%
- COVID products Comirnaty and Paxlovid declined 34% and 95% operationally, respectively
- Announced $1.0B additional cost savings in SIA and $1.5B in manufacturing optimization savings through 2029
- Completed $1.875B exit of ViiV Healthcare stake in Q1; closed Innovent Biologics licensing deal on July 10 (recorded in Q3)
- CFO Dave Denton to step down August 15; interim CFO Cecile Guegan appointed
Financial Impact
Adjusted EPS beat by 13% and revenue beat by 4.5%; revenue guidance raised by $500M at midpoint; impairments of $4.3B (non-cash) drive GAAP loss
Risk Factors
- Sustained COVID revenue decline could pressure overall growth as non-COVID products may not fully offset in future quarters
- $4.3B asset impairments signal clinical setbacks (sigvotatug vedotin ADC, Oxbryta), raising pipeline risk
- CFO departure introduces leadership uncertainty pending permanent replacement search
- Adjusted EPS guidance unchanged despite revenue raise, reflecting dilution from Innovent deal and cost investments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000078003-26-000094 |
| Document: pfe-20260804.htm | 0000078003-26-000094 |
| Document: 0000078003-26-000094-index-headers.html | 0000078003-26-000094 |
| Document: 0000078003-26-000094-index.html | 0000078003-26-000094 |
| Document: 0000078003-26-000094.txt | 0000078003-26-000094 |
| 8-K Data (Synthetic) | 0000078003-26-000094 |
Track record
21 reports on PFE
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +16.49% at T+60 after the Aug 5, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
- Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers